These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28024998)

  • 61. Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus.
    Omidfar K; Rasaee MJ; Modjtahedi H; Forouzandeh M; Taghikhani M; Bakhtiari A; Paknejad M; Kashanian S
    Tumour Biol; 2004; 25(4):179-87. PubMed ID: 15557755
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Generation and Characterization of Rat Monoclonal Antibodies Against Epidermal Growth Factor Receptor.
    Osaki T; Wang CX; Tachibana T; Azuma M; Kitamura M; Nakanishi T
    Monoclon Antib Immunodiagn Immunother; 2015 Dec; 34(6):418-22. PubMed ID: 26683181
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Analysis of the specificity and thermodynamics of the interaction between low affinity antibodies and carbohydrate antigens using fluorescence spectroscopy.
    Engström HA; Andersson PO; Ohlson S
    J Immunol Methods; 2005 Feb; 297(1-2):203-11. PubMed ID: 15777943
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Exploring the dynamic range of the kinetic exclusion assay in characterizing antigen-antibody interactions.
    Bee C; Abdiche YN; Stone DM; Collier S; Lindquist KC; Pinkerton AC; Pons J; Rajpal A
    PLoS One; 2012; 7(4):e36261. PubMed ID: 22558410
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Measurement of the dissociation rate constant of antigen/antibody complexes in solution by enzyme-linked immunosorbent assay.
    Larvor MP; Djavadi-Ohaniance L; Nall B; Goldberg ME
    J Immunol Methods; 1994 Apr; 170(2):167-75. PubMed ID: 8157995
    [TBL] [Abstract][Full Text] [Related]  

  • 66. An inhibition enzyme immunoassay for estimating relative antibody affinity and affinity heterogeneity.
    Rath S; Stanley CM; Steward MW
    J Immunol Methods; 1988 Feb; 106(2):245-9. PubMed ID: 3276795
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Alterations in monoclonal antibody affinity and antigenic receptor site expression on mycoplasma-infected human colorectal cancer cells.
    Oredipe OA; Barth RF; Rotaru JH; Hinkle GH; Steplewski Z
    Proc Soc Exp Biol Med; 1990 Sep; 194(4):301-7. PubMed ID: 2388904
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Determining Binding Affinity (KD) of Radiolabeled Antibodies to Immobilized Antigens.
    Belitzky E; Cavaliere A; Rajabimoghadam K; Marquez-Nostra B
    J Vis Exp; 2022 Jun; (184):. PubMed ID: 35815982
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Measurement of tumour reactive antibody and antibody conjugate by competition, quantitated by flow cytofluorimetry.
    Robins RA; Laxton RR; Garnett M; Price MR; Baldwin RW
    J Immunol Methods; 1986 Jun; 90(2):165-72. PubMed ID: 2424997
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Re-evaluation of the concept of functional affinity as applied to bivalent antibody binding to cell surface antigens.
    Ong GL; Mattes MJ
    Mol Immunol; 1993 Nov; 30(16):1455-62. PubMed ID: 8232331
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Digital Receptor Occupancy Assay in Quantifying On- and Off-Target Binding Affinities of Therapeutic Antibodies.
    Chou CK; Liu YL; Chen YI; Huang PJ; Tsou PH; Chen CT; Lee HH; Wang YN; Hsu JL; Lee JF; Yankeelov TE; Kameoka J; Yeh HC; Hung MC
    ACS Sens; 2020 Feb; 5(2):296-302. PubMed ID: 32073836
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Determining antibody stoichiometry using time-integrated fluorescence cumulant analysis.
    Skinner JP; Wu B; Mueller JD; Tetin SY
    J Phys Chem B; 2011 Feb; 115(5):1131-8. PubMed ID: 21192730
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Binding parameters of antibodies reacting with multivalent antigens: functional affinity or pseudo-affinity.
    Mattes MJ
    J Immunol Methods; 1997 Mar; 202(1):97-101. PubMed ID: 9075776
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.
    Chimalakonda AP; Yadav R; Marathe P
    AAPS J; 2013 Jul; 15(3):717-27. PubMed ID: 23588584
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Overlooked benefits of using polyclonal antibodies.
    Ascoli CA; Aggeler B
    Biotechniques; 2018 Sep; 65(3):127-136. PubMed ID: 30089399
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Analytical Method for Experimental Validation of Computer-Designed Antibody.
    Tanabe A; Tsumoto K
    Methods Mol Biol; 2023; 2552():409-433. PubMed ID: 36346606
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Calculation of monoclonal antibody affinity constants directly from antibody dilution curves.
    Griswold WR; Nelson DP
    Immunol Lett; 1985; 9(1):15-8. PubMed ID: 2580778
    [No Abstract]   [Full Text] [Related]  

  • 78. Detecting drug-target binding in cells using fluorescence-activated cell sorting coupled with mass spectrometry analysis.
    Wilson K; Webster SP; Iredale JP; Zheng X; Homer NZ; Pham NT; Auer M; Mole DJ
    Methods Appl Fluoresc; 2017 Dec; 6(1):015002. PubMed ID: 28901950
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Monoclonal Antibody 5F11G11.
    Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):196-197. PubMed ID: 28806155
    [No Abstract]   [Full Text] [Related]  

  • 80. Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.
    Lin TY; Park JA; Long A; Guo HF; Cheung NV
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34497115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.